The authors of this Perspective critically evaluate various artificial intelligence (AI)-based computational approaches used for digital pathology and provide a broad framework to incorporate these tools into clinical oncology, discussing challenges such as the need for well-curated validation datasets, regulatory approval and fair reimbursement strategies.
On September 27, 2024, the FDA granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for RET fusion-positive medullary thyroid cancer.
FDA approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with diagnosed multiple myeloma
On September 19, 2024, the FDA approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for non-small cell lung cancer.
On September 17, 2024, the FDA approved ribociclib (Kisqali, Novartis) and ribociclib and letrozole co-pack (Kisqali Femara Co-Pack, Novartis).
Nature Reviews Clinical Oncology – Patients with HER2+ breast cancer often respond to trastuzumab, although acquired resistance is common and can involve a range of…
Nature Reviews Clinical Oncology – Patients with HER2+ breast cancer often respond to trastuzumab, although acquired resistance is common and can involve a range of…
Nature Reviews Clinical Oncology – Patients with HER2+ breast cancer often respond to trastuzumab, although acquired resistance is common and can involve a range of…
Nature Reviews Clinical Oncology – Patients with HER2+ breast cancer often respond to trastuzumab, although acquired resistance is common and can involve a range of…
On September 12, 2024, the FDA approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous injection.
Nature Reviews Clinical Oncology – The development of clinically relevant artificial intelligence (AI) models has traditionally required access to extensive labelled datasets, which inevitably…
